학술논문
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
Document Type
Article
Author
Source
In Annals of Oncology June 2020 31(6):780-788
Subject
Language
ISSN
0923-7534